Fraser Murray
Amministratore Delegato presso Pheno Therapeutics Ltd.
Profilo
Fraser Murray is the founder of Pandeia Therapeutics Ltd.
(founded in 2019) and Pedanius Therapeutics Ltd.
(founded in 2018).
He is currently the Chief Executive Officer at Pheno Therapeutics Ltd., Director at Tridek-One Therapeutics SAS, and Head of Scientific Evaluation at Advent Venture Partners LLP.
Mr. Murray has an undergraduate degree from the University of Strathclyde, an MBA from Alliance Manchester Business School, and a doctorate from The School of Pharmacy University of London.
Posizioni attive di Fraser Murray
| Società | Posizione | Inizio |
|---|---|---|
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Corporate Officer/Principal | 01/01/2022 |
| Pandeia Therapeutics Ltd. | Fondatore | 01/01/2019 |
Pheno Therapeutics Ltd.
 Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Pheno Therapeutics Ltd. operates as a biotechnology company. The firm develops remyelinating therapies for the unmet need for a neuroprotective therapy for multiple sclerosis. The company was founded on October 31, 2018 and is headquartered in Edinburgh, the United Kingdom. | Amministratore Delegato | 01/11/2022 |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Direttore/Membro del Consiglio | - |
Formazione di Fraser Murray
| University of Strathclyde | Undergraduate Degree |
| The School of Pharmacy University of London | Doctorate Degree |
| Alliance Manchester Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Advent Venture Partners LLP
Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Finance |
| Pandeia Therapeutics Ltd. | |
Pheno Therapeutics Ltd.
Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Pheno Therapeutics Ltd. operates as a biotechnology company. The firm develops remyelinating therapies for the unmet need for a neuroprotective therapy for multiple sclerosis. The company was founded on October 31, 2018 and is headquartered in Edinburgh, the United Kingdom. | Commercial Services |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Commercial Services |
- Borsa valori
- Insiders
- Fraser Murray
